{"name":"Zymeworks Inc.","slug":"zymeworks","ticker":"ZYME","exchange":"NYSE","domain":"zymeworks.com","description":"Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,\nBritish Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.","hq":"Vancouver, BC, Canada","founded":0,"employees":"243","ceo":"Kenneth Galbraith","sector":"Biotech","stockPrice":23.7,"stockChange":-0.87,"stockChangePercent":-3.54,"marketCap":"$1.7B","metrics":{"revenue":81263000,"revenueGrowth":-91.1,"grossMargin":-67,"rdSpend":199752000,"netIncome":-211843000,"cash":364727008,"dividendYield":0,"peRatio":46,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"ZW985 patent cliff ($0.0B at risk)","drug":"ZW985","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"ZW732 patent cliff ($0.0B at risk)","drug":"ZW732","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ZW191","genericName":"ZW191","slug":"zw191","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ZW191","genericName":"ZW191","slug":"zw191","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Zymeworks Announces FDA Clearance of Investigational New Drug (IND) Application for ZW985","summary":"Zymeworks announced that the FDA has cleared the IND application for ZW985, enabling the company to proceed with clinical trials.","drugName":"ZW985","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Zymeworks Reports Third Quarter 2023 Financial Results","summary":"Zymeworks reported its third quarter 2023 financial results, highlighting progress in its pipeline and revenue growth.","drugName":"","sentiment":"neutral"},{"date":"2023-08-31","type":"deal","headline":"Zymeworks Enters into Collaboration Agreement with Merck KGaA","summary":"Zymeworks announced a collaboration agreement with Merck KGaA to develop and commercialize ZW732, a bispecific antibody targeting cancer.","drugName":"ZW732","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNcXZ1TzJFeTc3S29LeVI1V3g3bFR2dWFHbDY0U3ZaUFFEWWFYZmlBTXJTYmFVMkYxZGJSTGZDTjNoOWNENUZrTkt4WUNWNzI4Y3ZLdGtHajNfM0V0blVxNUxHWE9YMFZlWUNBWWFGeWJ1a0Q2YUNQV1BlVDlzR0tTZTZxdFJZRFdxZ01OVHc1R2VGaGNzNHppTkM0WXMxX1k0TkpuWXBkeUd2XzYycTF5cnBIQ1RPMU5HNWxPTUk1TU9nazJuQmgwbnJTaWRZMHc?oc=5","date":"2026-04-01","type":"pipeline","source":"globenewswire.com","summary":"Zymeworks Appoints Kristin Stafford as Chief Financial Officer - globenewswire.com","headline":"Zymeworks Appoints Kristin Stafford as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNWUluNUpYLThJcUNFRk5nRGV0UkJ3c21UMHpWQ3dmTkt1eGlDdWhRNWdULV9rZHlnLXBLNnRsd29CM1dWWFNWaGY2dnVmQUE2djNXMXE0OGpNUVJzSFNHbmUtbzByb0F1ZzUwNzM4NEI5MUhiTzlMNEVIMXljcGc3dnRNQXJNLVVaQzIxYVdXYXBGNWNCc1pkQ3N5b1JETGdnbFJwM3lMUDVIaHdTNUE?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks - Stock Titan","headline":"Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOdE0xNVFTTXlyckRvZzhISXJlaUdMUTU0RzZReUZHRUFmUVBaOVpLQmtXZUJUeXd3dHZFNGd5S2l0SjVTbGpOSmFfQnJrek1XQUV3TVYwRUs2VjVVTlNfc2Y3bTZCVHBwRXJRNWV5amFuNnptVy1DdmVlYTQzUzY1UDV3VVpBY0E?oc=5","date":"2026-03-02","type":"pipeline","source":"Yahoo Finance","summary":"Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Yahoo Finance","headline":"Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQNG5ZeldrVV80eUM1dzYtVlA3WGVJMXRjak5QU05ybEpvQzA4Nks2aTl2T25lbzlmb0hlbTdVQkN4a2lDYnVHUk91WkdMQXRoYzkxMl90aFprbExWbXFHTHMzVlY5dmhBUFpEaWNmZmk5aUtKNzF3cUV6Ml8zN0Nyd1VxUWI1YkRFa0FWS0tOUUNjM0gzVUp4OUgwNzZjZmxTT1ln?oc=5","date":"2026-03-02","type":"deal","source":"The Pharma Letter","summary":"Zymeworks and Royalty Pharma enter into $250 million deal - The Pharma Letter","headline":"Zymeworks and Royalty Pharma enter into $250 million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeUNmYlU3WkstSXRlV0M1di0xOWRYT1R4akFEbTdIWVZOWHpYMktFMm5rM0dDNkszcjVNU2M3WkxLZWwtRDhON2Q3OHFkS0xNLUVhQ0s5czdfcUxiYzhLeGE1X18xa2JXRy1xU1dhN2phUVo2cmxud0c0NklHNlJKYy1WN01FVUx2TXh5ZUo3bmxIaXdWY0xINURFaGdUMjVkc2tvNGJwQnJLS0U2alh3Q2NIWW1NWFRtMWVUMnk0c3VsQ0ZwSmg5RmxVcFJGWGU4RVE?oc=5","date":"2026-03-02","type":"pipeline","source":"ChartMill","summary":"Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - ChartMill","headline":"Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPTTIwWklxdkNQdHBWdkl4UWRVdWNKQkFKU1lFOElaZ2xKWFJ1ZmxKMTkydG9RVHFnR05tNTFIQ2R5ckp2emVVbUlnLVNMeXh4OFU1S0M0Q0FEVWFvTFhqeUljdmUxLXR2SjczelRaaFpCOVFKcHprS19lS1hfTVRfSTlELUdUNTZXYTg1OTFpZTNMNmRrclJqeTdWV2lrRHRPT1JCaQ?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan","headline":"Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRnMyamlQM3NNX3p1X2Q4YVNvT0g4UENnTEpiMGp2MTZMV191dm1YR3VhWTZUWHVwY2VmbjFSQ3djQURQRE5HallQODd0NzNiY2VqcExza3NwenJETklEeTZFTHFhbENad1JNMkNXLUZEVk12T1g5bngyOHFtTThzZkcxZjBtUGR0V1hIQ3NlcmpXSEJ2Mjc4bllMMFk5Tk1qSUNKWHVIdG4?oc=5","date":"2025-12-11","type":"pipeline","source":"Business in Vancouver","summary":"Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Business in Vancouver","headline":"Could Zymeworks' blockbuster drug success revive Vancouver biotech scene?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxONmxvUmVpc3RXRTNOdGlWRUNUdmRzclFjOURHQnJiY2JtYUliaEFsamVuWDNEMk5FaUhvVjQtTjNsam1WUnE2Q25yQ0RWUy1mYkFnM1N0b1B5d1hUOGZMRXF6T25RMDlRWU5yaWg1enAzYzREVjdHRTdINlhYdmlzWVhvZ1cxSEJnUXk4Zng2SzVqWW9qc1U4Tm5UY1dJSVBWbWNGdkZpVmhGZw?oc=5","date":"2025-11-24","type":"pipeline","source":"The Globe and Mail","summary":"Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan - The Globe and Mail","headline":"Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNWjdxYm9iSDd6NjhLXzFWeWI5SDk0cjhxTk1TXzhiOUh2SjEtMTRJckJhdDdOcWdWb2hwZ211UklVckN2eWMzRUVVdmZQR0lwbTRUN3g4V254QkVnUENDZHRiTlRkZGtKcDFaYUhxQkVta1o3bHBpZnJaM0t0M1RHUmVGQTdYTTNQcUtPMm8zWFJ0My1WamxXZ2ZCRU52QjE1VmF0dXgydzVhM1lwUHNjazVhN25wQkNPQmc3NTFn?oc=5","date":"2025-11-18","type":"pipeline","source":"Fierce Pharma","summary":"With Ziihera wins rolling in, Zymeworks rolls out plan to become 'royalty-driven organization' - Fierce Pharma","headline":"With Ziihera wins rolling in, Zymeworks rolls out plan to become 'royalty-driven organization'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxONVdXa09sRjU0V2RpSEhoVHMyZWlYN3RfRnQxMWd0ZEJqNUZpNENpSlZEWjVuR2p2TE1KaXNPNWRWVGJsSkVYZllWMWIteGFWMDFEQWFmZE5EeklsZVM5VEw5enFmR0NYd0xuUXdtRmU4d1phcjZaVWlnd2R0MkxIQ0EyblFRZ1RYU2hGUWZSQXFIUEhVcGlaYl9Vbw?oc=5","date":"2025-11-17","type":"pipeline","source":"Barron's","summary":"Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. - Barron's","headline":"Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZWhDb1F4UWVFOXNBZFNES3NfQ3BBUkc4bmZSSmdONjRYQjNUMENaWk9jLVdLSVJSYVRXMnQxanRFd19EazJOMXlrSDlHU1NSdm8zbHhiUlhnMjByUHVaYnBZbFBmZ0h3em1DM2J1QWkwWE5VU25tZ1BJckxVdVBiekRvQVFZc05QanAtbFg5RV81RjJlaGppLWhFMWJIU21JQzNyU2xDU1FkckZWNDNYUA?oc=5","date":"2025-11-17","type":"pipeline","source":"Seeking Alpha","summary":"Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise (NASDAQ:JAZZ) - Seeking Alpha","headline":"Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise (NASDAQ:JAZZ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOaE02cjVia1hoa0RGX1otZ1lRajd4R1E3ZzQ5NHRlOHVfbDV3VkpCdUxpREpfSmkwMkNmU1U3aWI3M1RYUFZOS0YtNzZaNU1lSDU2YzFMQU83Z3dyNUljTzF3V2lWd3dsSVZlOVJyRjRKYmJabnpSRHFIUmF1SzJRTC15WVJzZ2RMSkluRUVyUElwZWlBN1l2TWhCMnBIdFZlTEUwUTRZMFNfRnRQYkV2U25ZbHhQREtBQjhOOG5oaDhySU9XZUdZenhTMFFzclE?oc=5","date":"2025-11-17","type":"pipeline","source":"Benzinga","summary":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga","headline":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday","sentiment":"neutral"},{"date":"2022-10-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-10-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-10-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"ZW985","drugSlug":"zw985","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"ZW732","drugSlug":"zw732","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Amgen","Biogen","Gilead Sciences"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":26680000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":26680000,"period":"2021-12-31"},{"value":38951000,"period":"2020-12-31"},{"value":29544000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":199752000,"rdSpendHistory":[{"period":"2025-12-31","value":137000000},{"period":"2024-12-31","value":134621000},{"period":"2023-12-31","value":143619000},{"period":"2022-12-31","value":208596000}],"sgaSpend":61500000,"operatingIncome":-92535000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-92535000},{"period":"2024-12-31","value":-119817000},{"period":"2023-12-31","value":-138007000},{"period":"2022-12-31","value":130486000}],"netIncome":-211843000,"netIncomeHistory":[{"period":"2025-12-31","value":-81130000},{"period":"2024-12-31","value":-122695000},{"period":"2023-12-31","value":-118674000},{"period":"2022-12-31","value":124341000}],"eps":-1.08,"epsHistory":[{"period":"2025-12-31","value":-1.08},{"period":"2024-12-31","value":-1.62},{"period":"2023-12-31","value":-1.72},{"period":"2022-12-31","value":1.9}],"cash":41157000,"cashHistory":[{"period":"2025-12-31","value":41157000},{"period":"2024-12-31","value":66103000},{"period":"2023-12-31","value":157557000},{"period":"2022-12-31","value":400912000}],"totalAssets":389132000,"totalLiabilities":78026000,"totalDebt":18267000,"equity":268501000,"operatingCashflow":-33005000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-33005000},{"period":"2024-12-31","value":-110058000},{"period":"2023-12-31","value":-118324000},{"period":"2022-12-31","value":144109000}],"capex":-2352000,"capexHistory":[{"period":"2025-12-31","value":-2352000},{"period":"2024-12-31","value":-3066000},{"period":"2023-12-31","value":-4077000},{"period":"2022-12-31","value":-13125000}],"freeCashflow":-35357000,"dividendsPaid":null,"buybacks":-41695000,"employees":243,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":15400000,"ebit":-44120000,"ebitda":-42113000,"period":"2025-12-31","revenue":2515000,"epsBasic":-0.55,"netIncome":-41209000,"rdExpense":31235000,"epsDiluted":-0.55,"grossProfit":null,"operatingIncome":-44120000},{"sga":14100000,"ebit":-22064000,"ebitda":-19480000,"period":"2025-09-30","revenue":27614000,"epsBasic":-0.26,"netIncome":-19602000,"rdExpense":35578000,"epsDiluted":-0.26,"grossProfit":null,"operatingIncome":-22064000},{"sga":14900000,"ebit":-623000,"ebitda":2591000,"period":"2025-06-30","revenue":48726000,"epsBasic":0.03,"netIncome":2317000,"rdExpense":34449000,"epsDiluted":0.03,"grossProfit":null,"operatingIncome":-623000},{"sga":17000000,"ebit":-25628000,"ebitda":-22323000,"period":"2025-03-31","revenue":27110000,"epsBasic":-0.3,"netIncome":-22636000,"rdExpense":35738000,"epsDiluted":-0.3,"grossProfit":null,"operatingIncome":-25628000},{"sga":16200000,"ebit":-22232000,"ebitda":-18543000,"period":"2024-12-31","revenue":31031000,"epsBasic":-0.31,"netIncome":-23506000,"rdExpense":37063000,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":-22232000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":23.7,"previousClose":24.57,"fiftyTwoWeekHigh":29.75,"fiftyTwoWeekLow":10.93,"fiftyTwoWeekRange":"10.93 - 29.75","fiftyDayAverage":25.72,"twoHundredDayAverage":21.5,"beta":1.19,"enterpriseValue":1446491648,"forwardPE":46,"priceToBook":6.59,"priceToSales":21.46,"enterpriseToRevenue":17.8,"enterpriseToEbitda":-13.42,"pegRatio":0,"ebitda":-107788000,"ebitdaMargin":-132.6,"freeCashflow":-45503000,"operatingCashflow":-75316000,"totalDebt":17042000,"debtToEquity":10.4,"currentRatio":10.82,"returnOnAssets":-15.8,"returnOnEquity":-42,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":13,"targetMeanPrice":40.15,"targetHighPrice":58,"targetLowPrice":31,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.3,"institutionHeldPercent":100.6,"sharesOutstanding":73023061,"floatShares":68142930,"sharesShort":4648225,"shortRatio":7.62,"shortPercentOfFloat":6.3,"epsTrailing":-1.37,"epsForward":0.52,"revenuePerShare":1.08,"bookValue":3.6,"officers":[{"age":63,"name":"Mr. Kenneth H. Galbraith C.A.","title":"Chairman of the Board, CEO & President"},{"age":57,"name":"Dr. Paul A. Moore Ph.D.","title":"Chief Scientific Officer"},{"age":34,"name":"Mr. Scott  Platshon","title":"Executive VP & Chief Business Officer"},{"age":42,"name":"Ms. Kristin  Stafford CPA","title":"Executive VP & CFO"},{"age":56,"name":"Mr. Mark  Hollywood","title":"Executive VP & Chief Operating Officer"},{"age":null,"name":"Ms. Shrinal  Inamdar","title":"VP of Investor Relations"},{"age":null,"name":"Ms. Diana  Papove B.Com.","title":"Vice President of Corporate Communications"},{"age":null,"name":"Dr. Lindsey  Foulkes B.Sc., Ph.D.","title":"SVP of Corporate Development & Strategy"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.zymeworks.com","phone":"302 274 8744"}}